Comparison of the cost-effectiveness of various therapies for common prostatic disorders.

abstract：:Although decision making about what drugs to include in an institutional formulary appears to lend itself readily to quantitative techniques such as decision analysis and cost-benefit analysis, a review of the literature reveals that very little has been published in this area. Several of the published decision analy...

journal_title：PharmacoEconomics

authors： Schechter CB

更新日期：1993-06-01 00:00:00

abstract：BACKGROUND:Before the new round of healthcare reform in China, primary healthcare providers could obtain a fixed 15 % or greater mark-up of profits by prescribing and selling medicines. There were concerns that this perverse incentive was a key cause of irrational medicine use. China's new Essential Medicines Program (...

journal_title：PharmacoEconomics

authors： Chen M,Wang L,Chen W,Zhang L,Jiang H,Mao W

更新日期：2014-03-01 00:00:00

abstract：OBJECTIVE:A cost-effectiveness analysis of oral capecitabine versus intravenous bolus 5-fluorouracil/l-leucovorin (FU/LV) as adjuvant therapy in patients with stage 3 colon cancer was performed from a Japanese healthcare payer perspective. METHODS:Adjuvant therapy comprised 24 weeks of treatment with either oral capec...

journal_title：PharmacoEconomics

authors： Shiroiwa T,Fukuda T,Shimozuma K,Ohashi Y,Tsutani K

更新日期：2009-01-01 00:00:00

abstract：:Discrete choice experiments (DCEs) are regularly used in health economics to elicit preferences for healthcare products and programmes. There is growing recognition that DCEs can provide more than information on preferences and, in particular, they have the potential to contribute more directly to outcome measurement ...

journal_title：PharmacoEconomics

authors： Lancsar E,Louviere J

更新日期：2008-01-01 00:00:00

abstract：:In this paper we consider the evolving American healthcare landscape and what it means for the use of economic evaluation of health interventions. We emphasise that use of economic evaluation in the US is unlikely to follow the European, Canadian or Australian models, which use cost effectiveness openly and explicitly...

journal_title：PharmacoEconomics

authors： Neumann PJ,Sullivan SD

更新日期：2006-01-01 00:00:00

abstract：:Several randomised comparative trials have shown that granulocyte colony-stimulating factor (G-CSF) reduces the duration of neutropenia, hospitalisation and intravenous antibacterial use in patients with cancer who are receiving high-dosage antineoplastic therapy. However, one area that has received less attention is ...

journal_title：PharmacoEconomics

authors： Dranitsaris G,Altmayer C,Quirt I

更新日期：1997-06-01 00:00:00

abstract：:To review and critically evaluate published cost-utility analyses (CUAs) pertaining to pharmaceuticals for the past 3 decades. We examined data from the Tufts Medical Center Cost-Effectiveness Analysis Registry (www.cearegistry.org), which contains detailed information on English-language CUAs and their ratios (in $US...

journal_title：PharmacoEconomics

authors： Neumann PJ,Fang CH,Cohen JT

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:Heart failure (HF) is a well-recognized public health concern and imposes high economic and societal costs. Decision analytic models exist for evaluating the economic ramifications associated with HF. Despite this, studies that appraise these modelling approaches for augmenting best-practice decisions remain...

journal_title：PharmacoEconomics

authors： Di Tanna GL,Bychenkova A,O'Neill F,Wirtz HS,Miller P,Ó Hartaigh B,Globe G

更新日期：2019-03-01 00:00:00

abstract：:There is a global perspective to the economic consequences of diabetes, which is illustrated in the many publications now being produced on this subject. Because of the higher prevalence of type II diabetes, its impact is greater than that of type I diabetes in both developed and developing countries (but particularly...

journal_title：PharmacoEconomics

authors： Williams R

更新日期：1995-01-01 00:00:00

abstract：AIM:To estimate the direct and indirect costs of morbidity and mortality attributable to alcohol consumption in Germany from a societal perspective in 2002. METHODS:Using the concept of attributable risks and the prevalence-based approach, age- and gender-specific alcohol-attributable fractions for morbidity and morta...

journal_title：PharmacoEconomics

authors： Konnopka A,König HH

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:In many healthcare systems, affordability concerns can lead to restrictions on the use of expensive efficacious therapies. However, there does not appear to be any consensus as to the terminology used to describe affordability, or the thresholds used to determine whether new drugs are affordable. OBJECTIVES...

journal_title：PharmacoEconomics

authors： Antoñanzas F,Terkola R,Overton PM,Shalet N,Postma M

更新日期：2017-08-01 00:00:00

abstract：BACKGROUND:To reach the French market, a new drug requires a marketing authorization (MA) and price and reimbursement agreements. These hurdles could delay access to new and promising drugs. Since 1992, French law authorizes the use of unlicensed drugs on an exceptional and temporary basis through a compassionate-use p...

journal_title：PharmacoEconomics

authors： Degrassat-Théas A,Paubel P,Parent de Curzon O,Le Pen C,Sinègre M

更新日期：2013-04-01 00:00:00

abstract：:In a recent leading article in PharmacoEconomics, Nuijten described some methods for incorporating uncertainty into health economic models and for utilising the information on uncertainty regarding the cost effectiveness of a therapy in resource allocation decision-making. His proposals are found to suffer from seriou...

journal_title：PharmacoEconomics

authors： O'Hagan A,McCabe C,Akehurst R,Brennan A,Briggs A,Claxton K,Fenwick E,Fryback D,Sculpher M,Spiegelhalter D,Willan A

更新日期：2005-01-01 00:00:00

abstract：:A number of health-related QOL (HR-QOL) measures specifically designed for people with diabetes mellitus have appeared in the literature. This article provides a selective review of 12 measures that address this important construct. For each included study, a description of the measure and its development phase is pro...

journal_title：PharmacoEconomics

authors： Watkins K,Connell CM

更新日期：2004-01-01 00:00:00

abstract：:Advanced controlled release (CR) dosage forms are relative newcomers to pharmaceutical markets, and few studies relate their efficacy, safety or compliance benefits to economic value. This literature review was undertaken to assess the cost effectiveness of CR dosage forms using such measures as purchase costs, total ...

journal_title：PharmacoEconomics

authors： Cramer MP,Saks SR

更新日期：1994-06-01 00:00:00

abstract：BACKGROUND:Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory lung disease associated with increasing morbidity and mortality and an economic burden that stretches beyond the patient to healthcare systems. Avoiding exacerbations and subsequent hospitalizations is an important clinical aim and ca...

journal_title：PharmacoEconomics

authors： Mittmann N,Hernandez P,Mellström C,Brannman L,Welte T

更新日期：2011-05-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Patient heterogeneity is the part of variability that can be explained by certain patient characteristics (e.g. age, disease stage). Population reimbursement decisions that acknowledge patient heterogeneity could potentially save money and increase population health. To date, however, economic ...

journal_title：PharmacoEconomics

authors： Grutters JP,Sculpher M,Briggs AH,Severens JL,Candel MJ,Stahl JE,De Ruysscher D,Boer A,Ramaekers BL,Joore MA

更新日期：2013-02-01 00:00:00

abstract：:The pharmacoeconomics of the low molecular weight heparin (LMWH) enoxaparin in the prophylaxis and treatment of venous thromboembolism have mostly been investigated in cost-effectiveness studies that estimated direct costs associated with treatment, using decision analyses and clinical outcome data from randomised con...

journal_title：PharmacoEconomics

authors： Bergqvist D

更新日期：2002-01-01 00:00:00

abstract：:The development of evidence to demonstrate 'value for money' is regarded as an important step in facilitating the search for the optimal allocation of limited resources and has become an essential component in healthcare decision making. Real-world evidence collected from de-identified individuals throughout the conti...

journal_title：PharmacoEconomics

authors： Kolasa K,Ken Redekop W,Berler A,Zah V,Asche CV

更新日期：2020-10-01 00:00:00

abstract：:Clinical and economic factors that are important to consider when selecting anaesthesia for day-case surgery can differ from those for inpatient anaesthesia. Patients undergoing day-case surgery tend to be healthier and have shorter durations of surgery. They expect less anxiety before surgery, amnesia for the surgica...

journal_title：PharmacoEconomics

authors： Eger EI,White PF,Bogetz MS

更新日期：2000-03-01 00:00:00

abstract：:Our objective was to assess the quality of reporting of original economic research articles in PharmacoEconomics from inception to the end of 1995, in order to identify areas of strength and weakness, and analyse trends over time. Each regular issue of the journal was examined for original economic evaluations. Accept...

journal_title：PharmacoEconomics

authors： Iskedjian M,Trakas K,Bradley CA,Addis A,Lanctôt K,Kruk D,Ilersich AL,Einarson TR

更新日期：1997-12-01 00:00:00

abstract：OBJECTIVE:To estimate the potential savings in overall cardiovascular disease (CVD) treatment costs for the US population with coronary artery disease (CAD) resulting from the use of amlodipine. STUDY DESIGN AND METHODS:Using patient-level data from a retrospective analysis of the Prospective Evaluation of the Vascula...

journal_title：PharmacoEconomics

authors： Casciano R,Doyle JJ,Chen J,Arikian S,Casciano J,Kugel H,Arocho R

更新日期：2002-01-01 00:00:00

abstract：BACKGROUND:During the 1990s, a number of new cytotoxic agents with clinically relevant activity in non-small-cell lung cancer (NSCLC), and with a more favourable therapeutic index than drugs already in use, became available. Given the high prices of these new drugs and the large number of patients affected, it is impor...

journal_title：PharmacoEconomics

authors： Neymark N,Lianes P,Smit EF,van Meerbeeck JP

更新日期：2005-01-01 00:00:00

abstract：:Multiple sclerosis (MS) is a disease of the CNS, typically striking adults during the primary productive time of their life. The symptoms of MS can restrict the individual's physical activity and income-earning ability, resulting in a major financial burden on the patient, family, health system and society. This syste...

journal_title：PharmacoEconomics

authors： Naci H,Fleurence R,Birt J,Duhig A

更新日期：2010-01-01 00:00:00

abstract：BACKGROUND:Like other developed countries with aging populations, Sweden is expecting large increases in the prevalence of Alzheimer's disease and corresponding escalations in the cost of care for patients with this disease. Galantamine, a new acetylcholinesterase inhibitor and nicotinic modulator, has proved effective...

journal_title：PharmacoEconomics

authors： Garfield FB,Getsios D,Caro JJ,Wimo A,Winblad B

更新日期：2002-01-01 00:00:00

abstract：OBJECTIVE:Economic evaluations of new diabetes therapies rely heavily upon the UK Prospective Diabetes Study (UKPDS) equations for prediction of cardiovascular events; however, concerns persist regarding their relevance to current clinical practice and appropriate use in populations other than newly diagnosed patients....

journal_title：PharmacoEconomics

authors： McEwan P,Bennett H,Ward T,Bergenheim K

更新日期：2015-02-01 00:00:00

abstract：:Disease management is a systematic approach to a health condition or a healthcare intervention that organises preventative, interventional and care approaches throughout the continuum of care and which measures outcomes in terms of populations, not individuals. Disease management's advantage over the current component...

journal_title：PharmacoEconomics

authors： Chang K,Nash D

更新日期：1998-07-01 00:00:00

abstract：OBJECTIVE:The aim of this review is to provide a summary of the literature on risk-sharing agreements, including conceptual, theoretical and empirical (number of agreements and their achievements) perspectives, and stakeholders'  perceptions. METHODS:We conducted a systematic literature search in MEDLINE from 2000 to ...

journal_title：PharmacoEconomics

authors： Antonanzas F,Juárez-Castelló C,Lorente R,Rodríguez-Ibeas R

更新日期：2019-12-01 00:00:00

abstract：AIM:To determine the economic impact (cost-benefit analysis) of childhood varicella vaccination, with the Oka/Merck varicella zoster virus vaccine live (Varivax) in Italy. METHODS:This analysis is based on an epidemiological model of varicella zoster virus (VZV) dynamics adapted to the Italian situation. Cost data (Eu...

journal_title：PharmacoEconomics

authors： Coudeville L,Brunot A,Giaquinto C,Lucioni C,Dervaux B

更新日期：2004-01-01 00:00:00

abstract：:Germany is in a period of transition with regard to healthcare reform. The number and intensity of cost control interventions increased during the last decade in an attempt to contain healthcare expenditure. The German legislature has implemented long term macroeconomic measures such as contribution rate stability and...

journal_title：PharmacoEconomics

authors： Ulrich V,Wille E

更新日期：1996-01-01 00:00:00